Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07190222 · ClinicalTrials.gov registry record · Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
A Phase 3 study of Chronic Obstructive Pulmonary Disease, sponsored by Sanofi.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 942
- Enrollment target
- 20
- Study locations
NCT07190222 is a Phase 3 study of Chronic Obstructive Pulmonary Disease that is actively recruiting participants, run by Sanofi. The registered enrollment target is 942 participants, below the 1,743-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (46% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT07190222, a Phase 3 study of Chronic Obstructive Pulmonary Disease, is actively recruiting participants, sponsored by Sanofi.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 942 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a parallel, Phase 2b/Phase 3, 3-arm study to investigate the efficacy, safety, and tolerability of subcutaneous (SC) treatment with lunsekimig compared with placebo in adult participants (aged 40 to 80 years, inclusive) with inadequately controlled Chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype. Participation to the study consists of 3 periods: * Screening period of up to 4 weeks * Randomized intervention period of approximately 48 weeks * Follow-up period: Approximately 8 weeks The study duration will be up to 60 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Lunsekimig
Study Locations (20)
Florida
- Hillcrest Medical Research- Site Number : 8400082 - DeLand
- Finlay Medical Research - Greenacres- Site Number : 8400107 - Greenacres City
- Direct Helpers Research Center- Site Number : 8400057 - Hialeah
- Pulmonary Specialists of the Palm Beaches- Site Number : 8400017 - Loxahatchee Groves
- DL Research Solutions- Site Number : 8400140 - Miami
- Phoenix Medical Research - Miami - 24th Street- Site Number : 8400027 - Miami
- Professional Research Center- Site Number : 8400046 - Miami
- Research Institute of South Florida- Site Number : 8400028 - Miami
- Innovations Biotech- Site Number : 8400019 - Miami
- Heuer M.D. Research- Site Number : 8400018 - Orlando
- Florida Institute for Clinical Research- Site Number : 8400001 - Orlando
- Avanza Medical Research Center- Site Number : 8400015 - Pensacola
- Hull and Hull Medical Specialists- Site Number : 8400002 - Plantation
California
- Ark Clinical Research- Site Number : 8400113 - Long Beach
- Alliance Clinical - West Hills- Site Number : 8400067 - Los Angeles
- California Medical Research Associates - Northridge- Site Number : 8400089 - Northridge
Colorado
- Alpine Clinical Research Center - Boulder - 47th Street- Site Number : 8400005 - Boulder
- Critical Care Pulmonary & Sleep Associates- Site Number : 8400081 - Lakewood
Arizona
- Tucson Clinical Research Institute- Site Number : 8400006 - Tucson
Georgia
- Appalachian Clinical Research- Site Number : 8400060 - Adairsville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 942 participants |
| Start Date | 2025-09-17 |
| Est. Completion | 2030-01-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07190222
The ClinicalTrials.gov registry entry for NCT07190222 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 942 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,743-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (46% lower). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07190222 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT07190222 about?
NCT07190222 is a clinical study titled "Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype". This is a parallel, Phase 2b/Phase 3, 3-arm study to investigate the efficacy, safety, and tolerability of subcutaneous (SC) treatment with lunsekimig compared with placebo in adult participants (aged 40 to 80 years, inclusive) with inadequately controlled Chronic obstructive pulmonary disease (COPD...
What is the current status of trial NCT07190222?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 942 participants. The study started on 2025-09-17. Estimated completion is 2030-01-22.
What conditions does trial NCT07190222 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease.
What interventions are being tested in trial NCT07190222?
The interventions under investigation include: Placebo (DRUG), Lunsekimig (DRUG).
Who is sponsoring clinical trial NCT07190222?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07190222 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
RECRUITING · Phase 3
-
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
RECRUITING · Phase 3
-
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
ACTIVE NOT RECRUITING · Phase 3
-
A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 3
-
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation
COMPLETED · Phase 3
-
AMPLIFY - D6571C00001 Duaklir USA Phase III Study
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.